ES2196396T3 - Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa. - Google Patents

Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.

Info

Publication number
ES2196396T3
ES2196396T3 ES97954988T ES97954988T ES2196396T3 ES 2196396 T3 ES2196396 T3 ES 2196396T3 ES 97954988 T ES97954988 T ES 97954988T ES 97954988 T ES97954988 T ES 97954988T ES 2196396 T3 ES2196396 T3 ES 2196396T3
Authority
ES
Spain
Prior art keywords
inhibitors
factor
sulfur
containing oxygen
members containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97954988T
Other languages
English (en)
Inventor
James Russell Pruitt
John Matthew Fevig
Mimi Lifen Quan
Donald Joseph Phillip Pinto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ES2196396T3 publication Critical patent/ES2196396T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL OXIGENO Y AL AZUFRE QUE CONTIENEN HETEROAROMATICOS Y SUS DERIVADOS, DE LA FORMULA (I), O SALES O PROMEDICAMENTOS FARMACEUTICAMENTE ACEPTABLES QUE LOS CONTIENEN, EN LA CUAL J REPRESENTA O O S Y D PUEDE REPRESENTAR C(=NH)NH 2 , QUE SON UTILES COMO INHIBIDORES DEL FA CTOR XA.
ES97954988T 1996-12-23 1997-12-18 Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa. Expired - Lifetime ES2196396T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77181496A 1996-12-23 1996-12-23
US87976397A 1997-06-20 1997-06-20

Publications (1)

Publication Number Publication Date
ES2196396T3 true ES2196396T3 (es) 2003-12-16

Family

ID=27118522

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97954988T Expired - Lifetime ES2196396T3 (es) 1996-12-23 1997-12-18 Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.

Country Status (8)

Country Link
EP (1) EP0946528B1 (es)
JP (1) JP2001506271A (es)
AT (1) ATE236890T1 (es)
AU (1) AU6645998A (es)
CA (1) CA2276034A1 (es)
DE (1) DE69720773T2 (es)
ES (1) ES2196396T3 (es)
WO (1) WO1998028282A2 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7976998A (en) * 1997-06-19 1999-01-04 Du Pont Merck Pharmaceutical Company, The (amidino)6-membered aromatics as factor xa inhibitors
AU3127900A (en) * 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
US6545054B1 (en) 1999-02-11 2003-04-08 Millennium Pharmaceuticals, Inc. Alkenyl and alkynyl compounds as inhibitors of factor Xa
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
JP2003500386A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
JP2004507439A (ja) 1999-07-16 2004-03-11 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー Ｘａ因子阻害剤としての窒素含有ヘテロ二環式化合物
ES2316383T3 (es) * 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
NZ517828A (en) * 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
DE10008329A1 (de) * 2000-02-23 2001-08-30 Merck Patent Gmbh Aminosulfonylbiphenylderivate
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
DE10027025A1 (de) * 2000-05-31 2001-12-06 Merck Patent Gmbh Clycinamide
AU2001268711A1 (en) 2000-06-23 2002-01-08 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
BR0112292A (pt) 2000-06-23 2003-06-24 Bristol Myers Squibb Pharma Co Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
EP1340749A4 (en) 2000-11-17 2007-09-05 Takeda Pharmaceutical ISOXAZOLE DERIVATIVES
WO2002083667A2 (en) 2001-04-13 2002-10-24 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
CN110894196A (zh) 2001-09-21 2020-03-20 百时美-施贵宝控股爱尔兰无限公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
EP1432687A2 (en) * 2001-10-03 2004-06-30 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
AU2003273179A1 (en) 2002-05-10 2003-12-12 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
US7273866B2 (en) 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
PL209303B1 (pl) * 2002-12-23 2011-08-31 4Sc Ag Związek aromatyczny, kompozycja farmaceutyczna zawierająca związek aromatyczny i zastosowanie związku aromatycznego jako środka przeciwzapalnego, immunomodulującego i antyproliferacyjnego
TWI336696B (en) * 2003-01-27 2011-02-01 Astellas Pharma Inc Thiazole derivatives
CA2515726C (en) * 2003-02-11 2012-07-10 Vernalis (Cambridge) Limited Isoxazole compounds
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
HRP20110180T1 (hr) * 2003-07-23 2011-04-30 Synta Pharmaceuticals Corporation Spojevi za upotrebu kod upala i upotrebe vezane uz imunitet
WO2005012269A1 (ja) 2003-08-05 2005-02-10 Ajinomoto Co., Inc. 新規アゾール化合物
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
JP4881159B2 (ja) * 2004-03-18 2012-02-22 株式会社アールテック・ウエノ チアゾール誘導体を含む水性組成物
JP2007531773A (ja) 2004-03-31 2007-11-08 レキシコン・ジェネティクス・インコーポレーテッド プロテインキナーゼ変調剤としての２−アミノメチルチアゾール−５−カルボキサミド
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
KR20140018997A (ko) 2005-01-07 2014-02-13 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
EA015034B1 (ru) 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-анилин-4-арилзамещенные тиазольные производные
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP2077995B1 (en) 2006-11-02 2012-02-08 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
JP2010509392A (ja) 2006-11-13 2010-03-25 ファイザー・プロダクツ・インク ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
ES2424023T3 (es) 2007-10-18 2013-09-26 Janssen Pharmaceutica N.V. 1,2,4-triazoles trisustituidos
CA2714662C (en) 2008-03-19 2016-05-10 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators
CL2009001125A1 (es) 2008-05-09 2011-02-11 Janssen Pharmaceutica Nv Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
WO2010068775A2 (en) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (es) 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
SG186229A1 (en) 2010-06-07 2013-01-30 Novomedix Llc Furanyl compounds and the use thereof
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN103596947A (zh) 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
NZ701290A (en) 2012-04-30 2016-08-26 Medimmune Ltd Pyrrolobenzodiazepines
KR101960130B1 (ko) 2012-04-30 2019-03-19 메디뮨 리미티드 피롤로벤조디아제핀
UY34832A (es) 2012-05-31 2013-12-31 Phenex Pharmaceuticals Ag TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
US20160052898A1 (en) 2013-03-20 2016-02-25 Bayer Pharma Aktiengesellschaft Novel compounds
CN105228982B (zh) 2013-03-20 2018-03-27 拜耳制药股份公司 用于治疗过度增殖性病症的3‑乙酰基氨基‑1‑(苯基‑杂芳基‑氨基羰基或苯基‑杂芳基‑羰基氨基)苯衍生物
TW201506024A (zh) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物
JP6522602B2 (ja) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
HUE046914T2 (hu) 2014-10-08 2020-04-28 Redx Pharma Plc N-piridinil-acetamid-származékok, mint a WNT jelátviteli út inhibitorai
HRP20220864T8 (en) 2014-10-08 2023-02-03 Redx Pharma Plc N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
CN107250120A (zh) 2015-02-20 2017-10-13 拜耳制药股份公司 作为Wnt信号通路抑制剂的1,3,4‑噻二唑‑2‑基‑苯甲酰胺衍生物
EP3259251A1 (en) 2015-02-20 2017-12-27 Bayer Pharma Aktiengesellschaft N-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathways
CN107531634A (zh) 2015-02-20 2018-01-02 拜耳制药股份公司 作为wnt信号通路抑制剂的3‑氨基甲酰基苯基‑4‑甲酰胺和间苯二甲酰胺衍生物
CN106243058B (zh) * 2016-07-28 2018-06-29 三峡大学 一种化合物在制备抑制激肽释放酶klk7的药物上的应用及其合成方法
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
CN113004207B (zh) * 2021-03-05 2023-10-17 中国医科大学 Plk4小分子抑制剂的化合物及其应用
WO2024103400A1 (zh) * 2022-11-18 2024-05-23 水木未来(北京)科技有限公司 作为gpr75激活剂的多环化合物、包含其的药物组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132006T2 (de) * 1990-11-30 2000-08-03 Otsuka Pharmaceutical Co., Ltd. Thiazolederivate als inhibitoren von aktivem sauerstoff
US5317103A (en) * 1991-01-15 1994-05-31 Merck Sharp & Dohme Limited Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists
WO1994024095A1 (en) * 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5668159A (en) * 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists

Also Published As

Publication number Publication date
DE69720773D1 (de) 2003-05-15
ATE236890T1 (de) 2003-04-15
WO1998028282A2 (en) 1998-07-02
CA2276034A1 (en) 1998-07-02
WO1998028282A3 (en) 1998-09-17
AU6645998A (en) 1998-07-17
EP0946528B1 (en) 2003-04-09
JP2001506271A (ja) 2001-05-15
DE69720773T2 (de) 2004-01-29
EP0946528A2 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
ATE230392T1 (de) Amidinophenyl-pyrrolidine, -pyrroline und - isoxazolidine und ihre derivate
MY119820A (en) Guanidine mimics as factor xa inhibitors
AR020305A1 (es) HETEROAROMATICOS CON CONTENIDO DE NITROGENO COMO INHIBIDORES DEL FACTOR Xa.
ATE248824T1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
ATE264846T1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
TR200103764T2 (tr) Mutilin türevleri ve bunların antibakteriyeller olarak kullanımları
TR200100917T2 (tr) Aril ve heteroaril sübstitüentli heteroksiklik üreler kullanılarak RAF kinazın inhibe edilmesi
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DE69716925D1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
NO20001483L (no) Nye NPY-agonister
TR200002605T2 (tr) Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
SE9701304D0 (sv) Compounds
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
PT992509E (pt) Novos derivados macrolidos
TR200001010T2 (tr) Ürokinaz önleyicileri olan izokinolinler.
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
ATE224358T1 (de) Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung
NO934760D0 (no) Arylsubstituerte heterosykliske forbindelser
NO934758D0 (no) Alkylsubstituerte heterosykliske forbindelser
AP2002002595A0 (en) Heterocyclic amide derivatives.
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.